Australia's chief medical officer has insisted the AstraZeneca vaccine is safe and there is currently no evidence it causes ...

Chronic urticaria is occasionally challenging, but dermatologists and allergists can help each other as well as the patient by combining their unique skills in difficult cases.

AstraZeneca has unveiled its innovative oral GLP-1 medication, elecoglipron, which stands to transform the treatment ...

Are we still going to use it? Can we just scrap it? Do we have enough Pfizer? With more changing health advice and discussion ...

AstraZeneca's Clean Heat Program is turning industrial heat decarbonization into a hedge against energy volatility — and a core business strategy.

AI can speed up drug discovery and decrease attrition rates in the clinic, but it is important to recognize that both are ...

We've seen 80% adoption in 12 months, in a federal agency with a reduced headcount. The private sector has fewer excuses than ...

Rare genetic variants known to cause cardiomyopathy, an inherited cause of a weak heart, can increase the risk of patients developing heart failure. However, new research from Mass General Brigham ...

How One Marketing Problem Led to a New Approach to Business Communication Most successful companies start by solving a ...

Weight-loss pills will be sold by supermarket chains and pharmacies after regulators approve them. Morrisons, Boots, ...

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen ® ...

Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.